+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07085767

Phase 3 Study Comparing Palazestrant Plus Ribociclib Versus Letrozole Plus Ribociclib for First-Line Treatment of ER, HER2- Advanced Breast Cancer

Led by Olema Pharmaceuticals, Inc. · Updated on 2026-09-23

1000

Participants Needed

200

Research Sites

160 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a phase 3 clinical trial comparing two treatment combinations for adults with ER-positive, HER2-negative advanced breast cancer who have not received prior systemic anti-cancer treatment for this condition. The study aims to evaluate the effectiveness and safety of palazestrant combined with ribociclib versus letrozole combined with ribociclib. Participants include men and women with locally advanced or metastatic breast cancer not suitable for curative therapy. Participants are randomly assigned to one of two groups. One group receives palazestrant 90 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching letrozole daily. The other group receives letrozole 2.5 mg once daily, ribociclib 600 mg once daily on days 1-21 of a 28-day cycle, and a placebo matching palazestrant daily. Treatment cycles repeat every 28 days, and the study includes approximately 1,000 participants worldwide. During the study, participants will be monitored for disease progression and overall survival, with primary measurements taken from the date of randomization until disease progression or death, estimated up to 3.5 years. Safety, drug levels, and patient-reported health outcomes will be assessed regularly. The trial includes long-term follow-up for up to 5.5 years to evaluate overall survival. Participants will have scheduled visits for assessments and monitoring throughout their involvement in the trial.

CONDITIONS

Brief Title

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Research Team

O

Olema Pharmaceuticals, Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here